ANI PHARMACEUTICALS, INC Share-based Payment Arrangement, Expense
ANI PHARMACEUTICALS, INC (ANIP) reported Share-based Payment Arrangement, Expense of $14.30 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2023-03-09
- ANI PHARMACEUTICALS, INC share-based payment arrangement, expense for the quarter ending 2018-12-31 was $1.80M, a 21.24% increase year-over-year.
- ANI PHARMACEUTICALS, INC share-based payment arrangement, expense for the quarter ending 2018-09-30 was $1.77M, a 21.20% increase year-over-year.
- ANI PHARMACEUTICALS, INC share-based payment arrangement, expense for the quarter ending 2018-06-30 was $1.76M, a 0.84% decline year-over-year.
- ANI PHARMACEUTICALS, INC share-based payment arrangement, expense for the quarter ending 2018-03-31 was $1.36M, a 0.80% decline year-over-year.
- ANI PHARMACEUTICALS, INC share-based payment arrangement, expense for fiscal 2022 was $14.30M, a 37.50% increase from fiscal 2021.
- ANI PHARMACEUTICALS, INC share-based payment arrangement, expense for fiscal 2021 was $10.40M, a 18.75% decline from fiscal 2020.
- ANI PHARMACEUTICALS, INC share-based payment arrangement, expense for fiscal 2020 was $12.80M, a 40.66% increase from fiscal 2019.
- ANI PHARMACEUTICALS, INC share-based payment arrangement, expense for fiscal 2019 was $9.10M, a 35.82% increase from fiscal 2018.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | $14.30M 10-K · filed 2023-03-09 | ||||||
| 2021-12-31 | $10.40M 10-K · filed 2023-03-09 | ||||||
| 2020-12-31 | $12.80M 10-K · filed 2023-03-09 | ||||||
| 2019-12-31 | $9.10M 10-K · filed 2022-03-15 | ||||||
| 2018-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $3.58M derived: sum of 2 quarters · filed 2021-03-11 | $5.34M derived: sum of 3 quarters · filed 2021-03-11 | $6.70M 10-K · filed 2021-03-11 | |||
| 2018-09-30 | $1.77M 10-Q · filed 2018-11-06 | $3.54M derived: sum of 2 quarters · filed 2018-11-06 | $4.90M 10-Q · filed 2018-11-06 | $6.38M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-06-30 | $1.76M 10-Q · filed 2018-08-07 | $3.12M 10-Q · filed 2018-08-07 | $4.61M derived: sum of 3 quarters · filed 2020-02-27 | $6.07M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-03-31 | $1.36M 10-Q · filed 2018-05-08 | $2.85M derived: sum of 2 quarters · filed 2020-02-27 | $4.31M derived: sum of 3 quarters · filed 2020-02-27 | $6.09M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2017-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $2.95M derived: sum of 2 quarters · filed 2020-02-27 | $4.73M derived: sum of 3 quarters · filed 2020-02-27 | $6.10M 10-K · filed 2020-02-27 | $6.02M 10-K · filed 2018-02-27 | ||
| 2017-09-30 | $1.46M 10-Q · filed 2018-11-06 | $3.24M derived: sum of 2 quarters · filed 2018-11-06 | $4.61M 10-Q · filed 2018-11-06 | $6.04M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2017-06-30 | $1.78M 10-Q · filed 2017-08-03 | $3.15M 10-Q · filed 2018-08-07 | $4.58M derived: sum of 3 quarters · filed 2019-02-27 | $5.93M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2017-03-31 | $1.37M 10-Q · filed 2018-05-08 | $2.80M derived: sum of 2 quarters · filed 2019-02-27 | $4.15M derived: sum of 3 quarters · filed 2019-02-27 | $6.37M derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2016-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $2.78M derived: sum of 2 quarters · filed 2019-02-27 | $5.00M derived: sum of 3 quarters · filed 2019-02-27 | $6.10M 10-K · filed 2019-02-27 | |||
| 2016-09-30 | $1.35M 10-Q · filed 2017-11-02 | $1.36M 10-Q · filed 2016-11-03 | $3.57M derived: sum of 2 quarters · filed 2017-11-02 | $4.67M 10-Q · filed 2017-11-02 | $4.69M 10-Q · filed 2016-11-03 | $5.81M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-06-30 | $2.22M 10-Q · filed 2017-08-03 | $3.32M 10-Q · filed 2017-08-03 | $4.46M derived: sum of 3 quarters · filed 2018-02-27 | $5.58M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | $1.10M 10-Q · filed 2017-05-04 | $2.24M derived: sum of 2 quarters · filed 2018-02-27 | $3.36M derived: sum of 3 quarters · filed 2018-02-27 | $4.39M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $2.26M derived: sum of 2 quarters · filed 2018-02-27 | $3.29M derived: sum of 3 quarters · filed 2018-02-27 | $3.86M 10-K · filed 2018-02-27 | $3.90M 10-K · filed 2016-02-23 | ||
| 2015-09-30 | $1.12M 10-Q · filed 2016-11-03 | $2.15M derived: sum of 2 quarters · filed 2016-11-03 | $2.72M 10-Q · filed 2016-11-03 | ||||
| 2015-06-30 | $1.03M 10-Q · filed 2016-08-04 | $1.60M 10-Q · filed 2016-08-04 | |||||
| 2014-12-31 | $3.40M 10-K · filed 2017-03-02 | ||||||
| 2014-03-31 | $47.00K 10-Q · filed 2014-05-12 | ||||||
| 2013-12-31 | $36.00K 10-K · filed 2016-02-23 | ||||||
| 2013-03-31 | $145.79K 10-Q · filed 2013-05-10 | ||||||
| 2011-12-31 | $1.18M 8-K · filed 2013-01-28 | ||||||
| 2010-12-31 | $992.76K 8-K · filed 2013-01-28 | ||||||
| 2009-12-31 | $1.25M 8-K · filed 2013-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |